Global Cancer Immunotherapy Market

1 INTRODUCTION OF GLOBAL CANCER IMMUNOTHERAPYMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CANCER IMMUNOTHERAPYMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END USER:
5.1 Hospitals
5.2 Clinics & Others

6 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION:
6.1 Lung Cancer
6.2 breast cancer
6.3 Multiple Myeloma
6.4 Colorectal Cancer
6.5 Head & Neck Cancer
6.6 Prostate Cancer
6.7 Melanoma
6.8 Other Cancer Types

7 GLOBAL CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE:
7.1 Monoclonal Antibodies
7.1.1 Naked Monoclonal Antibodies
7.1.2 Conjugated Monoclonal Antibodies
7.1.3 Bispecific Monoclonal Antibodies
7.2 Vaccines
7.2.1 Prophylactic Vaccines
7.2.2 Therapeutic Vaccines
7.3 Checkpoint Inhibitors
7.3.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.3.2 Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
7.4 Cell Therapies
7.4.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.4.2 Dendritic Cells
7.5 Immuno modulators
7.5.1 Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf& G-Csf)
7.5.2 Interferons (IFN)
7.5.3 Interleukins (IL)
7.5.4 Oncolytic Virus

8 GLOBAL CANCER IMMUNOTHERAPYMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL CANCER IMMUNOTHERAPYMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Amgen Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Astrazeneca
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Bayer AG
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Bristol-Myers Squibb
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 ELI Lilly and Company
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Janssen Global Services, LLC (Johnson and Johnson)
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Merck
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Novartis
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Pfizer
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development

10.10 F. Hoffmann-La Roche Ltd
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development

11 Appendix
11.1 Related Reports